iRhythm Technologies reported strong preliminary Q4 2025 results with full-year revenue exceeding guidance and 2026 guidance of $870-880M (17-18% YoY growth). However, the stock fell ~20% due to the delay of Zio MCT launch to 2027 and 2026 guidance missing Street expectations. William Blair analyst Brandon Vazquez believes the selloff is overblown and maintains an Outperform rating, adding the stock to their Conviction List at 7x 2026 sales valuation.

NEXGEL reported stable Q3 2025 revenue of $2.9 million, improved gross profit margins, and narrowed adjusted EBITDA losses. The company signed new partnerships, launched product lines, and received non-dilutive financing from Stada, positioning for potential growth in Q4.

The global cardiac monitoring devices market is projected to grow from USD 21 billion in 2024 to USD 32 billion by 2032, driven by rising cardiovascular disease prevalence, technological advancements in remote monitoring, and increasing health awareness.

A clinical trial showed home-based long-term continuous ECG monitoring using Zio device increased atrial fibrillation detection and reduced time to diagnosis in patients aged 65+ with moderate to high stroke risk.

A shareholder filed a class action lawsuit against iRhythm Technologies, Inc. (IRTC), a digital healthcare company, alleging that the company misled investors about its Zio AT monitor. The court denied the defendants' motion to dismiss, allowing the litigation to proceed.

The AI in remote patient monitoring market is witnessing strong growth, driven by the increasing prevalence of chronic illnesses and a rise in product innovation, global investments in digital health infrastructure, and a focus on proactive, data-centric healthcare approaches.

iRhythm Technologies reported strong Q1 2025 results, with revenue growing 20.3% year-over-year driven by increased demand for its Zio services. The company's gross margin also improved, and it provided an upbeat guidance for fiscal 2025. Analysts have turned bullish on the stock, with Wells Fargo upgrading it to Overweight.

Kaskela Law LLC is investigating iRhythm Technologies, Inc. (IRTC) on behalf of long-term shareholders. A securities fraud complaint was filed against iRhythm, alleging the company made false and misleading statements about its Zio AT heart monitoring device.

The GUARD-AF trial found that screening for undiagnosed atrial fibrillation (AF) using iRhythm's Zio XT patch-based long-term continuous monitoring (LTCM) led to an increase in new AF diagnoses, but did not significantly reduce stroke hospitalization rates.

The article discusses the growing popularity of cannabis concentrates and identifies several strong-performing brands in key markets like Michigan and Massachusetts that could be attractive acquisition targets amid industry consolidation.

An executive at iRhythm Technologies sold $148,332 worth of the company's stock to cover tax obligations related to the vesting of Restricted Stock Units. The executive still retains a substantial holding of 27,255 shares in the company.

SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings.